2018 Winners

The 2018 winners are:

Best ADC Platform Technology
Sutro Biopharma (nnAA Conjugation) -WINNER
LegoChem Bio (Scaffold Based Approach) – Runner Up

Best New Drug Developer
Bicycle Therapeutics- WINNER 
Sutro Biopharma-Runner Up

Most Promising Clinical Candidate
Polatuzumab Vedotin- WINNER 
Sacituzumab Govitecan (IMMU-132)-Runner Up

Best Contract Manufacturing (CMO) Provider
BSP Pharmaceuticals- WINNER 
Novasep-Runner Up

Best Contract Research (CRO) Provider
Charles River- WINNER 
Abzena-Runner Up

Best Publication in 2017
Rovalpituzumab tesirine, a DLL3-targeted antibody-drugconjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Lancet Oncol. 2017 Jan;18(1):42-51.- WINNER 

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. J Clin Oncol. 2017 Jan 10;35(2):141-148.-Runner Up

Individual Input to the Field 2017
Philipp Mueller, Boehringer Ingelheim -WINNER 

Long Standing Contribution to the Field
Dr Ravi Chari, ImmunoGen – WINNER